SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yoo Jin, Kim, Seong-Eun, Park, Yong Eun, Chang, Ji Young, Song, Hyun Joo, Kim, Duk Hwan, Yang, Young Joo, Kim, Byung Chang, Lee, Jae Gon, Yang, Hee Chan, Choi, Miyoung, Myung, Seung-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081989/
https://www.ncbi.nlm.nih.gov/pubmed/34974674
http://dx.doi.org/10.5217/ir.2021.00098
Descripción
Sumario:Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

Ejemplares similares